DDInter268 DDInter661
Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to (vitamin D3) in the skin, which is then converted to in the liver and kidneys. undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity. Calcitriol is considered to be the most potent metabolite of vitamin D in humans. Renal production of calcitriol is stimulated in response to PTH
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition.
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Calcitriol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Dihydrotachysterol
Dihydrotachysterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sevelamer
Sevelamer {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Calcitriol {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is downregulated by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Calcitriol {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} may lead to a major life threatening interaction when taken with {v} Doxercalciferol
Doxercalciferol {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Cholecalciferol
Cholecalciferol {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Erdafitinib
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Calcitriol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Calcitriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Calcitriol (Compound) resembles Dihydrotachysterol (Compound) and Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Sevelamer and Sevelamer may lead to a major life threatening interaction when taken with Erdafitinib
Calcitriol (Compound) upregulates CTSD (Gene) and CTSD (Gene) is downregulated by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Calcitriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Calcitriol (Compound) upregulates CTSD (Gene) and CTSD (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Erdafitinib
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol (Compound) resembles Cholecalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Erdafitinib